Financial Sports Medicine Top Stories Overture Orthopaedics Announces Milestone $1.0M in Sales of its OvertureTi Knee Resurfacing System® to Relieve Pain and Dysfunction Associated with Articular Cartilage Lesions, Osteochondral Defects, and Early Osteoarthritis in the Knee byTim AllenDecember 31, 2025
Regulatory Sports Medicine Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain byTim AllenDecember 15, 2025
Neuro Sports Medicine SPRI and Neuromuscular Dynamics Launch NIH-Funded Clinical Trial to Advance Non-Surgical Knee Osteoarthritis Treatment byTim AllenNovember 18, 2025
Recon Regulatory Robotics Zimmer Biomet Receives U.S. FDA Clearance for Enhanced Version of ROSA® Knee Robotic Technology byJosh SandbergNovember 14, 2025
Regulatory Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee byJosh SandbergOctober 28, 2025
Financial Recon Knee Reconstruction Market Grew by $210 Million During 2024-2025; Set to Reach $5.09 Billion by 2032 – Technology and Patient Demands are Transforming Surgical Practice byJosh SandbergOctober 27, 2025
Extremities Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy byJosh SandbergOctober 21, 2025
Biologics Regulatory Doron Therapeutics Announces First Patients Dosed in Phase 3 Study of MOTYS (PTP-001) for the Treatment of Osteoarthritis of the Knee byTim AllenOctober 17, 2025
